secwatch.observer — SEC 8-K summary
======================================

Issuer:     ProMIS Neurosciences Inc. (PMN)
CIK:        0001374339
Form:       8-K
Filed at:   2026-01-30T23:59:59+00:00
Accession:  0001104659-26-008325
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ProMIS Neurosciences raises up to $175M in PIPE; extends cash runway into 2028
------------------------------------------------------------------------------

- Upfront gross proceeds ~$75M from ~6.8M common shares and 100K pre-funded warrants; up to ~$100M more from warrant exercise.
- Pricing: common shares at $10.77 (most) and $12.13 for insiders; warrants exercisable at $14.40.
- Warrants expire 60 days after PMN310 SAD topline data announcement or Feb 3, 2031.
- Proceeds to fund Phase 1b Alzheimer's study and subcutaneous PMN310 development; blinded 6-month data expected mid-2026.
- Co-led by Janus Henderson and Ally Bridge Group; CEO and board also participated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1374339/000110465926008325/0001104659-26-008325-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1374339/000110465926008325/pmn-20260129x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-008325

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer